Spironolactone
Product Images NDC 53808-0338

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 53808-0338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

This Is The Label For Spironolactone Tablets 100 mg (Spironolactone 100mg(qualitest))

This Is The Label For Spironolactone Tablets 100 mg (Spironolactone 100mg(qualitest))
FDA Label Image

This Is The Label For Spironolactone Tablets 25 mg (Spironolactone 25mg (qualitest))

This Is The Label For Spironolactone Tablets 25 mg (Spironolactone 25mg (qualitest))
FDA Label Image

This Is An Image Of The Structural Formula For Spironolactone. (Spironolactonetabs 1)

This Is An Image Of The Structural Formula For Spironolactone. (Spironolactonetabs 1)
This text appears to be describing the molecular formula and molecular weight of a chemical compound. The compound has the molecular formula of C,H,O,S and a molecular weight of 416.57. However, no information about the name or properties of the compound is provided.*
FDA Label Image

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)
This text seems to indicate results from a statistical analysis involving probability. Specifically, it mentions a "Log-rank p" value of less than 0.001, which likely indicates a statistically significant difference between groups being compared. Additionally, there is a timeline spanning 6 to 48 months. However, without more context or information, it is difficult to determine the exact nature of the analysis or its implications.*
FDA Label Image

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.